Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD 923 vs MSIR for breakthrough cancer pain
NCT00635063Phase 3Terminated
- Sponsor
- Nxera Pharma
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of AD-923 in breakthrough cancer pain (BTcP), sponsored by Nxera Pharma. Started Feb 2008; status: terminated.
02
Drugs
AD-923
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT00635063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00635063.